Holger Moch has contributed to the molecular characterization of cancer. The major goal of his research is the identification of clinically significant biomarkers for the prediction of prognosis and response to therapy. He made major contributions in uropathology and gynecopathology.
The majority of his studies were performed at the Institute of Pathology of the University Basle and at the Institute of Surgical Pathology of the University Zurich. The current research interests are focused on the relevance of the von Hippel‐Lindau protein for renal carcinoma initiation and metastases. His research led to a molecular progression model of renal cancer. A second research interest is related to the characterization of “differentiation‐“ and “Cancer testis‐antigens” in solid tumors. Novel molecular high throughput technologies, e.g. Comparative genomic hybridization, fluorescence and in situ hybridization and expression array analyses are tested for their potential in diagnostic pathology.